Fig. 7.

Albuleukin and rIL-2 inhibit hepatic tumor burden in C57B1/6 mice. Comparison of liver weights between groups demonstrated that both rIL-2 and Albuleukin strongly inhibited bulk tumor growth relative to the placebo and HSA control groups, respectively (p<0.05). No significant difference in liver weight was found between the Albuleukin and rIL-2 treatment groups. Mean ± SE are shown, n=12 mice per group. Statistical differences in liver weights between all groups were evaluated by one-way ANOVA. Individual t tests were conducted for pairwise comparisons